Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha reported Q1 financial results with a net loss of $42.4 million, or $0.12 per share, ending the quarter with $276.6 million in cash to fund operations into 2028. Operationally, the company reaffirmed FDA alignment on the BLA pathway for TSHA-102, supporting a potential submission based on a 6-month interim analysis of the REVEAL pivotal trial.
Key figures
- Revenue
- 0
- Drug Name
- TSHA-102
- Guidance
- Funded planned operating expenses into 2028
- Net loss
- 42400000
- Rnd expenses
- 33800000
- Cash position
- 276600000
- Shares outstanding
- 366632827
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.